Humanigen up on deal to make COVID-19 drug with French firm

Humanigen

09/02/2022 13:47

** Biopharmaceutical co Humanigen's shares  HGEN.O  rise
4.5% to $2.1 premarket
    ** Late on Tuesday, co announced partnership with
privately-held French firm Cenexi to manufacture potential
COVID-19 therapy Lenzilumab in France and the European Union
 urn:newsml:reuters.com:*:nBw2kNscca
    ** Co says initial step of the collaboration includes Cenexi
providing fill-and-finish services for lenzilumab for the next
five years
    ** Under the agreement, Humanigen will transfer the
technology and knowledge to Cenexi for the drug 
    ** Companies to hold talks to potentially expand the
agreement to other services Cenexi offers, including labeling
and packaging, importation of bulk drug substance and quality
release of materials in France and throughout Europe
    ** In EU, Humanigen expects to submit a conditional
marketing authorization with a request for accelerated approval
in Q3 
    ** Up to Tuesday's close, stock had fallen 91% in the last
12 months 

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))